<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370044</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIF</org_study_id>
    <nct_id>NCT01370044</nct_id>
  </id_info>
  <brief_title>Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures</brief_title>
  <acronym>CARDIF</acronym>
  <official_title>Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charité Neurocure AG Flöel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trail is to evaluate the efficacy of a Carbogen inhalation in
      patients with febrile seizures compared to a placebo-inhalation.

      Further aims are the evaluation of the safety of the Carbogen inhalation via a low-pressure
      can with a breathing mask in a home-setting, the manageability of the Carbogen inhalation
      via a low pressure can with a breathing mask in a home-setting or on the way (mobility), the
      quality of life of the parents and children using the low pressure can with a breathing mask
      in a home-setting or on the way (mobility) and the contentment and anxiety of the parents.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    results of interim analysis (not safety relevant)
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of patients which need Diazepam</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>efficacy of a Carbogen inhalation in patients with febrile seizures compared to a placebo inhalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of severe adverse events</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>safety of the Carbogen inhalation via a low-pressure can with a breathing mask in a home-setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>manageability of the application assessed by the parents</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>manageability of the Carbogen inhalation via a low pressure can with a breathing mask in a home-setting or on the way (mobility)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life of the parents and children after use of study medication</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>quality of life of the parents and children using the low pressure can with a breathing mask in a home-setting or on the way (mobility)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contentment and anxiety of the parents</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Febrile Seizure</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verum arm receiving Carbogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm receiving oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbogen</intervention_name>
    <description>3 minutes administration of carbogen</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 minutes administration of oxygen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  condition after febrile seizure

          -  age 12 months to 5 years

          -  written informed consent

        Exclusion Criteria:

          -  severe other organic disease

          -  meningitis as possible cause for the cerebral seizure

          -  neurologic disease or cerebral dysplasia

          -  cerebrale seizures without fever in the medical history

          -  hypersynchronic eeg activity

          -  disorder of the respiratory tract (Asthma e.g.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schülke-Gerstenfeld</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite - NeuroCure</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neurocure.de</url>
  </link>
  <reference>
    <citation>Ohlraun S, Wollersheim T, Weiß C, Martus P, Weber-Carstens S, Schmitz D, Schuelke M. CARbon DIoxide for the treatment of Febrile seizures: rationale, feasibility, and design of the CARDIF-study. J Transl Med. 2013 Jun 27;11:157. doi: 10.1186/1479-5876-11-157.</citation>
    <PMID>23806032</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 27, 2015</lastchanged_date>
  <firstreceived_date>May 20, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Markus Schülke-Gerstenfeld</name_title>
    <organization>Charite University Berlin</organization>
  </responsible_party>
  <keyword>Febrile Seizure</keyword>
  <keyword>Carbon Dioxide</keyword>
  <keyword>Carbogen</keyword>
  <keyword>Respiratory Alkalosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Seizures, Febrile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
